1e
19
1
49
2
2
18
1b
1d
18
33
85
1d
2 29
1d
25
Jonni S. Moore, Ph.D.
78
85
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
28
a8
3
78
Faculty Director, Penn Cytomics and Cell Sorting Shared Resource, University of Pennsylvania School of Medicine
77
member, Abrasion Cancer Center of the University of Pennsylvania
a9
Executive Director, Path BioResource, Department of Pathology and Laboratory Medicine, Perleman School of Medicine
74
member, Institute for Immunology, Perleman School of Medicine
86
Senior Advisor, Clinical Flow Cytometry, Hospital of University of Pennsylvania
65
member, Parker Center for Cancer Immunotherapy
8d
member, Immune Health Council, Perelman School of Medicine, University of Pennsylvania
95
Faculty Search Advisor, Perelman School of Medicine, Dept of Pathology and Laboratory Medicine
74
PSOM Lead Faculty Search Advisor, Perelman School of Medicine
11
Department: Pathology and Laboratory Medicine
4
1
23
1f
Graduate Group Affiliations
8
b
-
5c
- Immunology e
1d
46
Contact information
4e
4
3
3
1d
4e
211 and 297 John Morgan Building
35 3620 Hamilton Walk
Philadelphia, PA 19104
26
35 3620 Hamilton Walk
Philadelphia, PA 19104
30
Office: (215) 898-6853
34 Fax: (215) 898-4227
24
9b
12
34 Fax: (215) 898-4227
24
18
Publications
23 a
3
2
29
23 a
Links
185 Search PubMed for articles
67 Primary Work Website
41 Immunology graduate group faculty webpage.
c
4
b
1f
185 Search PubMed for articles
67 Primary Work Website
41 Immunology graduate group faculty webpage.
c
13
Education:
21 9 B.A. 14 (Biology) c
40 University of Virginia, Charlottesville, 1972.
21 a Ph.D. 19 (Microbiology) c
42 Thomas Jefferson University, Philadelphia, 1984.
c
3
3
3
3
8a
Permanent link21 9 B.A. 14 (Biology) c
40 University of Virginia, Charlottesville, 1972.
21 a Ph.D. 19 (Microbiology) c
42 Thomas Jefferson University, Philadelphia, 1984.
c
2 29
21
1e
1d
24
5e
a
275 Research in our laboratory centers on technology development with a focus on complex technologies, in particular cytomics. We pioneered new technology in flow cytometry liquid biopsies including the detection of extracellular vesicles as a rich source of prognostic and diagnostic information and developing this technology for diagnostics/prognostics in cardiovascular disease, traumatic brian injury and relapsing breast cancer. Most recently we have focused on the development of high dimensional deep phenotyping approaches for the identification of biomarkers of cancer responses using advance cytomic technology.
1e Current collaborators:
2e Lewis Chodosh, MD, PhD, Cancer Biology
39 Erica Carpenter, MBA, PhD, Department of Medicine
5f John Wherry, PhD, Department of Microbiology, Parker Institute for Cancer Immunotherapy
26 29
27
Description of Research Expertise
21 Research Summarya
275 Research in our laboratory centers on technology development with a focus on complex technologies, in particular cytomics. We pioneered new technology in flow cytometry liquid biopsies including the detection of extracellular vesicles as a rich source of prognostic and diagnostic information and developing this technology for diagnostics/prognostics in cardiovascular disease, traumatic brian injury and relapsing breast cancer. Most recently we have focused on the development of high dimensional deep phenotyping approaches for the identification of biomarkers of cancer responses using advance cytomic technology.
1e Current collaborators:
2e Lewis Chodosh, MD, PhD, Cancer Biology
39 Erica Carpenter, MBA, PhD, Department of Medicine
5f John Wherry, PhD, Department of Microbiology, Parker Institute for Cancer Immunotherapy
26 29
23
81 Jennifer Jakubowski, William Murphy, Derek D. Jones, Jacquelyn Thomas, Jonni S. Moore cf ,Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Penn Cytomics and Cell Sorting Resource Laboratory, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA 2 d5 : How to Build Effective Training Modalities in a Shared Resource Laboratory. CYTO 2025 annual meeting of ISAC-Denver June 2025 Notes: Peer reviewed poster presentation at CYTO 2025.
aa William Murphy1, Richard Schretzenmair1, Samantha Pearson1, Jennifer Jakubowski1, Derek Jones1, Robert Balderas2, Jonni Moore1 6a 1University of Pennsylvania, Penn Cytomics and Cell Sorting Shared Resource Laboratory, Philadelphia, PA 20 2BD Biosciences, Sane Jose, CA ab : Impact of Instrument Configuration and Compensation Methods on the Performance of a Large Library of Fluorochromes: Critical Concerns for Panel and Assay Design 7b Annual meeting of ISAC, CYTO 2025 June 2025 Notes: Peer-reviewed poster presentation at CYTO 2025.
61 Pearson, S., Schretzenmair, R., Moore, J., Jones, D. 2c : When the Powerhouse Powers Down: 86 Development of a Functional Flow Cytometric Panel to Identify Changes in Mitochondrial Phenotypes During Induced Cell Death Pathways 7f Annual meeting of ISAC, CYTO 2025 Denver June 2025 Notes: Peer-reviewed poster presented at CYTO 2025.
3cc Apostolia M. Tsimberidou, Farah A. Alayli, Kwame Okrah, Alexandra Drakaki, Danny N. Khalil, Shivaani Kummar, Saad A. Khan, F. Stephen Hodi, David Y. Oh, Christopher R. Cabanski, Shikha Gautam, Stefanie L. Meier, Meelad Amouzgar, Shannon M. Pfeiffer, Robin Kageyama, EnJun Yang, Marko Spasic, Michael T. Tetzlaff, Wai Chin Foo, Travis J. Hollmann, Yanyun Li, Matthew Adamow, Phillip Wong, Jonni S. Moore, Sharlene Velichko, Richard O. Chen, Dinesh Kumar, Samantha Bucktrout, Ramy Ibrahim, Ute Dugan, Lisa Salvador, Vanessa M. Hubbard-Lucey, Jill O’Donnell-Tormey, Sandra Santulli-Marotto, Lisa H. Butterfield, Diane M. Da Silva, Justin Fairchild, Theresa M. LaVallee, Lacey J. Padrón, Padmanee Sharma: Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. . J Exp Med 221: 221 (10), August 2024 Notes: ): e20240152. doi: https://doi.org/10.1084/jem.20240152 14
1bb Bellomo TR, Tsao NL, Johnston-Cox H, Borkowski K, Shakt G, Judy R, Moore J, Ractcliffe SJ, Fiehn O, Floyd TF, Wehrli FW, Mohler E, Newman JW, Damrauer SM. : Metabolite patterns associated with individual response to supervised exercise therapy in patients with intermittent claudication. JVS Vasc Sci. 3: 379-388, October 2022 Notes: doi: 10.1016/j.jvssci.2022.10.002.
241 Moen Sen, 1 Ryan M. Hausler, 1 Keely Dulmage, 2 Taylor A. Black, 1 William Murphy, 3 Charles H. Pletcher Jr, 3Ling Wang, 2 Chang Chen, 2 Stephanie S. Yee, 1 Scott J. Bornheimer, 4 Kara N. Maxwell, 1 Ben Z. Stanger, 5Jonni S. Moore, 3 Jeffrey C. Thompson, 6 and Erica L. Carpenter 1: Transcriptional profiling of single tumor cells from pleural effusions reveals heterogeneity of epithelial to mesenchymal transition and extra-cellular matrix marker expression. Clin Trans Med 12(7), July (online) 2022.
2e2 Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. : Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial Nat.Med. Nature Publishing Group, 28: 1167, 2022 Notes: doi: 10.1038/s41591-022-01829-9 28 Epub ahead of print.
138 Matthew Galsky, Karen Autio, Kristopher Wentzel, Julie Graff, Terence Friedlander, Julie Densmore,Christopher Cabanski, Kristin Shotts, Tim Howes, Jia Yu,Elaine Eisenbeisz, Marko Spasic,Stephen Maddock6 Diane DaSilva,Dinesh Kumar, Jonni Moore, Richard Schretzenmair, b7 Jennifer Lata, Arron Xu, Emma Reuschel, Snehal Wani, Matthew Morrow, Jeffrey Skolnik, Sandra Santulli-Marotto, Lacey Padron, Lisa Butterfield, Theresa LaVallee, Samantha Bucktrout, 9d Michael Yellin, Tibor Keler9 Lisa Salvador, Jill O'Donnell-Tourmey, Vanessa Lucey, Justin Fairchild, Ute Dugan, Nina Bhardwaj, Sumit Subudhi, Lawrence Fong 106 : 555 Clinical and pharmacodynamic biomarker results from PORTER, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant cancer patients. Journal for ImmunoTherapy of Cancer 10, 2022.
259 Habertheuer, Andreas; Ram, Chirag; Schmierer, Maggie; Chatterjee, Shampa; Hu, Robert; Freas, Andrew; Zielinski, Patrick; Rogers, Wade; Silvestro, Eva M; McGrane, Michael; Moore, Jonni S; Korutla, Laxminarayana; Siddiqui, Sarmad; Xin, Yi; Rizi, Rahim; Qin Tao, Jian; Kreisel, Daniel; Naji, Ali; Ochiya, Takahiro; Vallabhajosyula, Prashanth: Circulating Donor Lung-specific Exosome Profiles Enable Noninvasive Monitoring of Acute Rejection in a Rodent Orthotopic Lung Transplantation Model. Transplantation 106 (4): 754-766, 2022.
2c
7
1d
1f
Selected Publications
7c Shifu Tian, Charles H. Pletcher Jr., Hongen Wang, William Murphy, Jonni S. Moore 69 : Evaluating Micro-5 as a Biosafety Alternative to Cyclex-D in Novel Aerosol Containment Testing 7f ISAC Annual Meeting, Cyto 2025 Denver June 2025 Notes: Peer Reviewed Poster presentation at CYTO 2025.81 Jennifer Jakubowski, William Murphy, Derek D. Jones, Jacquelyn Thomas, Jonni S. Moore cf ,Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Penn Cytomics and Cell Sorting Resource Laboratory, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, PA 2 d5 : How to Build Effective Training Modalities in a Shared Resource Laboratory. CYTO 2025 annual meeting of ISAC-Denver June 2025 Notes: Peer reviewed poster presentation at CYTO 2025.
aa William Murphy1, Richard Schretzenmair1, Samantha Pearson1, Jennifer Jakubowski1, Derek Jones1, Robert Balderas2, Jonni Moore1 6a 1University of Pennsylvania, Penn Cytomics and Cell Sorting Shared Resource Laboratory, Philadelphia, PA 20 2BD Biosciences, Sane Jose, CA ab : Impact of Instrument Configuration and Compensation Methods on the Performance of a Large Library of Fluorochromes: Critical Concerns for Panel and Assay Design 7b Annual meeting of ISAC, CYTO 2025 June 2025 Notes: Peer-reviewed poster presentation at CYTO 2025.
61 Pearson, S., Schretzenmair, R., Moore, J., Jones, D. 2c : When the Powerhouse Powers Down: 86 Development of a Functional Flow Cytometric Panel to Identify Changes in Mitochondrial Phenotypes During Induced Cell Death Pathways 7f Annual meeting of ISAC, CYTO 2025 Denver June 2025 Notes: Peer-reviewed poster presented at CYTO 2025.
3cc Apostolia M. Tsimberidou, Farah A. Alayli, Kwame Okrah, Alexandra Drakaki, Danny N. Khalil, Shivaani Kummar, Saad A. Khan, F. Stephen Hodi, David Y. Oh, Christopher R. Cabanski, Shikha Gautam, Stefanie L. Meier, Meelad Amouzgar, Shannon M. Pfeiffer, Robin Kageyama, EnJun Yang, Marko Spasic, Michael T. Tetzlaff, Wai Chin Foo, Travis J. Hollmann, Yanyun Li, Matthew Adamow, Phillip Wong, Jonni S. Moore, Sharlene Velichko, Richard O. Chen, Dinesh Kumar, Samantha Bucktrout, Ramy Ibrahim, Ute Dugan, Lisa Salvador, Vanessa M. Hubbard-Lucey, Jill O’Donnell-Tormey, Sandra Santulli-Marotto, Lisa H. Butterfield, Diane M. Da Silva, Justin Fairchild, Theresa M. LaVallee, Lacey J. Padrón, Padmanee Sharma: Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer. . J Exp Med 221: 221 (10), August 2024 Notes: ): e20240152. doi: https://doi.org/10.1084/jem.20240152 14
1bb Bellomo TR, Tsao NL, Johnston-Cox H, Borkowski K, Shakt G, Judy R, Moore J, Ractcliffe SJ, Fiehn O, Floyd TF, Wehrli FW, Mohler E, Newman JW, Damrauer SM. : Metabolite patterns associated with individual response to supervised exercise therapy in patients with intermittent claudication. JVS Vasc Sci. 3: 379-388, October 2022 Notes: doi: 10.1016/j.jvssci.2022.10.002.
241 Moen Sen, 1 Ryan M. Hausler, 1 Keely Dulmage, 2 Taylor A. Black, 1 William Murphy, 3 Charles H. Pletcher Jr, 3Ling Wang, 2 Chang Chen, 2 Stephanie S. Yee, 1 Scott J. Bornheimer, 4 Kara N. Maxwell, 1 Ben Z. Stanger, 5Jonni S. Moore, 3 Jeffrey C. Thompson, 6 and Erica L. Carpenter 1: Transcriptional profiling of single tumor cells from pleural effusions reveals heterogeneity of epithelial to mesenchymal transition and extra-cellular matrix marker expression. Clin Trans Med 12(7), July (online) 2022.
2e2 Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, Yu JX, Pfeiffer SM, Spasic M, Xu J, Gherardini PF, Karakunnel J, Mick R, Alanio C, Byrne KT, Hollmann TJ, Moore JS, Jones DD, Tognetti M, Chen RO, Yang X, Salvador L, Wherry EJ, Dugan U, O'Donnell-Tormey J, Butterfield LH, Hubbard-Lucey VM, Ibrahim R, Fairchild J, Bucktrout S, LaVallee TM, Vonderheide RH. : Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial Nat.Med. Nature Publishing Group, 28: 1167, 2022 Notes: doi: 10.1038/s41591-022-01829-9 28 Epub ahead of print.
138 Matthew Galsky, Karen Autio, Kristopher Wentzel, Julie Graff, Terence Friedlander, Julie Densmore,Christopher Cabanski, Kristin Shotts, Tim Howes, Jia Yu,Elaine Eisenbeisz, Marko Spasic,Stephen Maddock6 Diane DaSilva,Dinesh Kumar, Jonni Moore, Richard Schretzenmair, b7 Jennifer Lata, Arron Xu, Emma Reuschel, Snehal Wani, Matthew Morrow, Jeffrey Skolnik, Sandra Santulli-Marotto, Lacey Padron, Lisa Butterfield, Theresa LaVallee, Samantha Bucktrout, 9d Michael Yellin, Tibor Keler9 Lisa Salvador, Jill O'Donnell-Tourmey, Vanessa Lucey, Justin Fairchild, Ute Dugan, Nina Bhardwaj, Sumit Subudhi, Lawrence Fong 106 : 555 Clinical and pharmacodynamic biomarker results from PORTER, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant cancer patients. Journal for ImmunoTherapy of Cancer 10, 2022.
259 Habertheuer, Andreas; Ram, Chirag; Schmierer, Maggie; Chatterjee, Shampa; Hu, Robert; Freas, Andrew; Zielinski, Patrick; Rogers, Wade; Silvestro, Eva M; McGrane, Michael; Moore, Jonni S; Korutla, Laxminarayana; Siddiqui, Sarmad; Xin, Yi; Rizi, Rahim; Qin Tao, Jian; Kreisel, Daniel; Naji, Ali; Ochiya, Takahiro; Vallabhajosyula, Prashanth: Circulating Donor Lung-specific Exosome Profiles Enable Noninvasive Monitoring of Acute Rejection in a Rodent Orthotopic Lung Transplantation Model. Transplantation 106 (4): 754-766, 2022.
2c